Fetrastobart vedotin vs Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Fetrastobart vedotin

Developed by Pfizer and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2028 · NCT05208762 (registry estimate)

No aligned efficacy figure on record for this race.

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

Marketed by Roche

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03735121 · Phase 3 · completed

This was a randomized, open-label, active-controlled phase 3 study comparing subcutaneous atezolizumab with the established IV formulation in previously treated NSCLC. The primary endpoints were pharmacokinetic measures (serum trough concentration and AUC) rather than clinical outcomes, and the non-inferiority comparisons were met for both. Because the study was open-label and the primary endpoints were surrogate PK measures, the evidence is limited despite the randomized design and adequate sample size.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFetrastobart vedotinTecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
PFS, median—Trial running · NCT07144280—Not reported
OS, median—Trial running · NCT07144280—Not reported
ORR—Trial running · NCT07144280—Not reported
Duration of response, median—Trial running · NCT07144280—Not reported

PFS, median

Fetrastobart vedotin
—Trial running · NCT07144280
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported

OS, median

Fetrastobart vedotin
—Trial running · NCT07144280
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported

ORR

Fetrastobart vedotin
—Trial running · NCT07144280
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported

Duration of response, median

Fetrastobart vedotin
—Trial running · NCT07144280
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Fetrastobart vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs): registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fetrastobart vedotin's landscape · Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)'s landscape